CPT code 86352 denotes a laboratory immunologic functional assay that measures immune system suppression by stimulating cells (for example, with antigen or mitogen) and detecting biomarkers such as adenosine triphosphate (ATP). This assay is used in clinical settings to evaluate cellular immune responsiveness, important for monitoring immune status in patients with suspected immunodeficiency, post-transplant immunosuppression, or systemic conditions affecting cell-mediated immunity. Nationally, the code matters because it denotes specialized laboratory testing that can influence therapeutic decisions and utilization of immunomodulatory therapies.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context for the assay, guidance on typical sites of service (clinical and hospital laboratories), and an outline of what national stakeholders commonly evaluate for this service: test purpose, service setting, and payer coverage considerations. Data not available in the input for detailed payer-specific reimbursement benchmarks, associated taxonomies, and ICD-10 mappings. The publication provides concise reference material for clinicians, laboratory managers, and policy analysts seeking a clear description of CPT code 86352 and its role in laboratory assessment of immune function.